---
title: Natural history of clonal haematopoiesis seen in real-world haematology settings
date: '2024-03-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38522849/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240325180626&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Recursive partitioning of healthy consortia led to the development of
  the Clonal Hematopoiesis Risk Score (CHRS) for clonal haematopoiesis (CH); however,
  in the practical setting, most cases of CH are diagnosed after patients present
  with cytopenias or related symptoms. To address this real-world population, we characterize
  the clinical trajectories of 94 patients with CH and distinguish CH harbouring canonical
  DNMT3A/TET2/ASXL1 mutations alone ('sole DTA') versus all other groups ...
disable_comments: true
---
Recursive partitioning of healthy consortia led to the development of the Clonal Hematopoiesis Risk Score (CHRS) for clonal haematopoiesis (CH); however, in the practical setting, most cases of CH are diagnosed after patients present with cytopenias or related symptoms. To address this real-world population, we characterize the clinical trajectories of 94 patients with CH and distinguish CH harbouring canonical DNMT3A/TET2/ASXL1 mutations alone ('sole DTA') versus all other groups ...